Vanguard Group’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $5.77M | Buy |
3,315,580
+602,708
| +22% | +$1.33M | ﹤0.01% | 3198 |
|
|
2025
Q3 | $6.35M | Buy |
2,712,872
+703,727
| +35% | +$1.35M | ﹤0.01% | 3193 |
|
|
2025
Q2 | $4.09M | Sell |
2,009,145
-19,815
| -1% | -$38K | ﹤0.01% | 3280 |
|
|
2025
Q1 | $3.31M | Buy |
2,028,960
+355,372
| +21% | +$713K | ﹤0.01% | 3317 |
|
|
2024
Q4 | $3.06M | Sell |
1,673,588
-124,372
| -7% | -$550K | ﹤0.01% | 3439 |
|
|
2024
Q3 | $10.4M | Buy |
1,797,960
+216,389
| +14% | +$1.78M | ﹤0.01% | 2938 |
|
|
2024
Q2 | $12.8M | Sell |
1,581,571
-12,814
| -0.8% | -$135K | ﹤0.01% | 2779 |
|
|
2024
Q1 | $22.1M | Sell |
1,594,385
-52,787
| -3% | -$456K | ﹤0.01% | 2550 |
|
|
2023
Q4 | $10.1M | Sell |
1,647,172
-25,731
| -2% | -$127K | ﹤0.01% | 2943 |
|
|
2023
Q3 | $7.81M | Buy |
1,672,903
+579
| +0% | +$3.2K | ﹤0.01% | 3028 |
|
|
2023
Q2 | $8.96M | Buy |
1,672,324
+150,265
| +10% | +$1.21M | ﹤0.01% | 3010 |
|
|
2023
Q1 | $15M | Buy |
1,522,059
+101,851
| +7% | +$1.74M | ﹤0.01% | 2740 |
|
|
2022
Q4 | $26.6M | Buy |
1,420,208
+138,349
| +11% | +$3.14M | ﹤0.01% | 2489 |
|
|
2022
Q3 | $26.5M | Buy |
1,281,859
+167,560
| +15% | +$4.29M | ﹤0.01% | 2506 |
|
|
2022
Q2 | $23.1M | Buy |
1,114,299
+176,972
| +19% | +$4.99M | ﹤0.01% | 2570 |
|
|
2022
Q1 | $40.4M | Buy |
937,327
+17,384
| +2% | +$783K | ﹤0.01% | 2409 |
|
|
2021
Q4 | $55.1M | Buy |
919,943
+6,894
| +0.8% | +$552K | ﹤0.01% | 2296 |
|
|
2021
Q3 | $78.4M | Buy |
913,049
+689
| +0.1% | +$69.1K | ﹤0.01% | 2115 |
|
|
2021
Q2 | $101M | Sell |
912,360
-45,082
| -5% | -$4.33M | ﹤0.01% | 2000 |
|
|
2021
Q1 | $107M | Buy |
957,442
+191,972
| +25% | +$25.2M | ﹤0.01% | 1915 |
|
|
2020
Q4 | $81.3M | Sell |
765,470
-13,717
| -2% | -$1.83M | ﹤0.01% | 1941 |
|
|
2020
Q3 | $108M | Sell |
779,187
-19,587
| -2% | -$4.08M | ﹤0.01% | 1649 |
|
|
2020
Q2 | $258M | Buy |
798,774
+332,598
| +71% | +$53.4M | 0.01% | 1109 |
|
|
2020
Q1 | $41.6M | Buy |
466,176
+45,143
| +11% | +$2.78M | ﹤0.01% | 1960 |
|
|
2019
Q4 | $16.7M | Sell |
421,033
-4,970
| -1% | -$150K | ﹤0.01% | 2618 |
|
|
2019
Q3 | $10.5M | Buy |
426,003
+20,986
| +5% | +$638K | ﹤0.01% | 2791 |
|
|
2019
Q2 | $14.3M | Buy |
405,017
+2,918
| +0.7% | +$116K | ﹤0.01% | 2672 |
|
|
2019
Q1 | $18M | Buy |
402,099
+23,173
| +6% | +$1.17M | ﹤0.01% | 2553 |
|
|
2018
Q4 | $18.2M | Buy |
378,926
+25,311
| +7% | +$1.54M | ﹤0.01% | 2491 |
|
|
2018
Q3 | $23.6M | Buy |
353,615
+15,371
| +5% | +$856K | ﹤0.01% | 2507 |
|
|
2018
Q2 | $15.9M | Buy |
338,244
+12,509
| +4% | +$690K | ﹤0.01% | 2673 |
|
|
2018
Q1 | $18.4M | Buy |
325,735
+1,997
| +0.6% | +$108K | ﹤0.01% | 2533 |
|
|
2017
Q4 | $16M | Buy |
323,738
+8,734
| +3% | +$541K | ﹤0.01% | 2593 |
|
|
2017
Q3 | $24M | Buy |
315,004
+46,069
| +17% | +$3.43M | ﹤0.01% | 2402 |
|
|
2017
Q2 | $25.3M | Buy |
268,935
+10,764
| +4% | +$921K | ﹤0.01% | 2358 |
|
|
2017
Q1 | $20.5M | Buy |
258,171
+18,905
| +8% | +$1.51M | ﹤0.01% | 2435 |
|
|
2016
Q4 | $19.9M | Buy |
239,266
+4,957
| +2% | +$448K | ﹤0.01% | 2423 |
|
|
2016
Q3 | $26.2M | Buy |
234,309
+1,462
| +0.6% | +$162K | ﹤0.01% | 2245 |
|
|
2016
Q2 | $25.8M | Buy |
232,847
+9,754
| +4% | +$1.18M | ﹤0.01% | 2216 |
|
|
2016
Q1 | $23.3M | Buy |
223,093
+16,428
| +8% | +$1.27M | ﹤0.01% | 2233 |
|
|
2015
Q4 | $16.7M | Buy |
206,665
+2,833
| +1% | +$226K | ﹤0.01% | 2385 |
|
|
2015
Q3 | $14.1M | Buy |
203,832
+13,124
| +7% | +$1.14M | ﹤0.01% | 2434 |
|
|
2015
Q2 | $18.7M | Buy |
190,708
+22,481
| +13% | +$2.4M | ﹤0.01% | 2389 |
|
|
2015
Q1 | $16.5M | Buy |
168,227
+7,288
| +5% | +$706K | ﹤0.01% | 2406 |
|
|
2014
Q4 | $17.7M | Buy |
160,939
+15,800
| +11% | +$1.93M | ﹤0.01% | 2286 |
|
|
2014
Q3 | $17.2M | Buy |
145,139
+5,269
| +4% | +$657K | ﹤0.01% | 2260 |
|
|
2014
Q2 | $18.1M | Buy |
139,870
+21,587
| +18% | +$2.55M | ﹤0.01% | 2250 |
|
|
2014
Q1 | $18.9M | Buy |
118,283
+34,411
| +41% | +$4.94M | ﹤0.01% | 2210 |
|
|
2013
Q4 | $11.7M | Buy |
83,872
+7,151
| +9% | +$716K | ﹤0.01% | 2393 |
|
|
2013
Q3 | $7.62M | Buy |
76,721
+4,429
| +6% | +$371K | ﹤0.01% | 2523 |
|
|
2013
Q2 | $2.76M | Buy |
+72,292
| New | +$2.19M | ﹤0.01% | 2952 |
|
Other funds holding INO
BCM
ACM
Vanguard Group's INO Position: Q4 2025 in Review
Vanguard Group increased its Inovio Pharmaceuticals (INO) stake by 22% in Q4 2025, buying an estimated $1.33M and bringing the position to 3,315,580 shares worth $5.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3198.
Vanguard Group first reported a position in INO in Q2 2013 and has held it in 51 quarters since. The position peaked at $258M in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.
- Vanguard Group held 3,315,580 shares of Inovio Pharmaceuticals worth $5.77M as of Q4 2025.
- Vanguard Group bought 602,708 Inovio Pharmaceuticals shares in Q4 2025, an estimated $1.33M.
- Inovio Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3198 holding.
- Vanguard Group first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Inovio Pharmaceuticals position peaked at $258M in Q2 2020.
- 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.